AvroBio Inc (AVRO) is a biotechnology company that specializes in developing gene therapies to treat rare genetic diseases. The company's proprietary lentiviral platform is designed to deliver a functional copy of a gene directly into a patient's own stem cells, which are then transplanted back into the patient's body. This approach is intended to provide a one-time curative treatment for genetic diseases.
AVRO's lead candidate, AVR-RD-01, is being developed as a potential treatment for Fabry disease, a rare genetic disorder that causes a buildup of a type of fat called globotriaosylceramide (Gb3) in the body's cells and tissues. The company is also developing gene therapies for other rare diseases, including Gaucher disease and cystinosis.
AVRO went public in 2018 and is traded on the NASDAQ stock exchange under the ticker symbol AVRO.
AvroBio Inc (AVRO) is a biotechnology company that specializes in developing gene therapies to treat rare genetic diseases. The company's proprietary lentiviral platform is designed to deliver a functional copy of a gene directly into a patient's own stem cells, which are then transplanted back into the patient's body. This approach is intended to provide a one-time curative treatment for genetic diseases.